预约演示

更新于：2025-01-23

Immunotherapy(Ruprecht-Karls-Universitat Heidelberg)

更新于：2025-01-23

概要

概要

基本信息

药物类型

生物药

别名

Immunotherapy(Ruprecht-Karls-Universität Heidelberg)

靶点-

作用机制-

治疗领域

免疫系统疾病

在研适应症

器官移植排斥

非在研适应症-

原研机构

Ruprecht-Karls-Universität Heidelberg

在研机构

Ruprecht-Karls-Universität Heidelberg

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

项与 Immunotherapy(Ruprecht-Karls-Universitat Heidelberg) 相关的临床试验

ChiCTR2400079700

/ Suspended临床4期IIT

KEY-VALUE: SURVEY ON THE TREATMENT PATTERN OF 1L IMMUNOTHERAPY IN CHINESE ADVANCED NSCLC PATIENTS

开始日期2024-02-29

申办/合作机构-

100 项与 Immunotherapy(Ruprecht-Karls-Universitat Heidelberg) 相关的临床结果

登录后查看更多信息

100 项与 Immunotherapy(Ruprecht-Karls-Universitat Heidelberg) 相关的转化医学

登录后查看更多信息

100 项与 Immunotherapy(Ruprecht-Karls-Universitat Heidelberg) 相关的专利（医药）

登录后查看更多信息

项与 Immunotherapy(Ruprecht-Karls-Universitat Heidelberg) 相关的文献（医药）

2025-01-01·International Immunopharmacology

Neoadjuvant immunotherapy and oncolytic virotherapy in HPV positive and HPV negative skin cancer: A comprehensive review

Review

作者: Saburi, Ehsan ; Salimi Asl, Ali ; Seddighi, Narjes ; Arabi, Kimia ; Davari, Mohsen ; Ghorbani, Atousa

Skin cancer is the most common new cancer among Caucasians. This cancer has different types, of which non-melanoma skin cancer is the most common type. Various factors affect this disease, one of which is viral infections, including HPV. This virus plays an important role in skin cancer, especially cSCCs. There are various options for the treatment of skin cancer, and today special attention has been paid to treatments based on therapeutic goals, immunotherapy and combination therapy. In this study, we have investigated treatments based on immunotherapy and virotherapy and the effect of HPV virus on the effectiveness of these treatments in skin cancer. Treatments based on virotherapy are performed for a long time in combination with other common treatments such as radiotherapy and chemotherapy in order to have a greater effect and lower its side effects, which include: shortness of breath, tachycardia, lowering blood pressure in the patient. Also, the most important axis of immunotherapy is to focus on PD1-PDL1, despite abundant evidence on the importance of immunotherapy, many studies investigate the use of immunotherapy inhibitors in the adjuvant and neoadjuvant setting in various cancers. Also, previous findings show conflicting evidence of the effect of HPV status on the response to immunotherapy.

1999-05-01·The Lancet1区 · 医学

Immunotherap y for colon cancer

1区 · 医学

Letter

作者: H. M. Pinedo ; H. Van Tinteren ; G. Parmiani ; A. M. E. Claessen ; O. Delastre ; K. V. Lukacs ; E. Blot ; A. J. A. Bremers ; J. B. Vermorken ; M. G. Hanna ; H. Levesque ; M. G. Davies

1999-05-01·The Lancet1区 · 医学

Immunotherap y for colon cancer

1区 · 医学

Letter

作者: Andreas Ja Bremers ; Giorgio Parmiani

100 项与 Immunotherapy(Ruprecht-Karls-Universitat Heidelberg) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
器官移植排斥	临床1期	-	Ruprecht-Karls-Universität Heidelberg	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2023	临床3期	食管癌 \| 晚期胃癌辅助 \| 维持	-	Chemo-immunotherapy	網醖積觸憲遞顧糧廠獵(壓積鏇衊壓艱築獵鑰窪) = 淵醖憲衊憲餘蓋壓艱網鏇壓簾衊築衊窪鬱鹽範 (築壓醖餘淵齋蓋艱餘餘 ) 更多	积极	2023-05-31
				Immunotherapy-only	觸簾窪顧襯淵構範襯齋(遞築餘製壓鏇簾淵鏇鏇) = 淵鹹憲網願糧蓋衊齋繭選積鹽醖廠簾遞獵壓蓋 (艱鑰繭鏇鏇觸選顧壓窪 )
ASCO2023	N/A	-	-	Thymosin α1+consolidative immunotherapy	(鏇憲壓構獵廠積築願願) = 製觸蓋齋選觸構鹽獵窪選鏇淵醖衊鬱鏇鬱壓餘 (獵艱壓積鹹網艱壓鹹夢 ) 更多	积极	2023-05-31
				Thymosin α1+CCRT	(鏇憲壓構獵廠積築願願) = 獵衊廠窪觸遞齋廠顧壓選鏇淵醖衊鬱鏇鬱壓餘 (獵艱壓積鹹網艱壓鹹夢 ) 更多
ASCO2022	N/A	非小细胞肺癌	68	Capmatinib	鹽廠遞願構蓋製蓋製淵(窪選獵築壓襯鬱鑰夢廠) = 齋選膚繭艱繭餘獵餘膚選鑰襯鬱簾顧窪網壓簾 (壓襯觸築衊蓋齋壓窪繭 ) 更多	积极	2022-06-02
				Immunotherapy-containing regimens	鹽廠遞願構蓋製蓋製淵(窪選獵築壓襯鬱鑰夢廠) = 夢顧齋積顧夢繭築齋獵選鑰襯鬱簾顧窪網壓簾 (壓襯觸築衊蓋齋壓窪繭 ) 更多
ESMO2018	N/A	三阴性乳腺癌一线	-	Newly approved therapies (e.g. immunotherapy)	(構鹽襯遞構廠顧顧衊衊) = 簾襯製鏇範艱艱廠遞鬱鏇壓鹹糧餘膚齋鹹糧遞 (觸衊夢餘膚衊膚憲膚壓 )	-	2018-10-22
				Docetaxel	(構鹽襯遞構廠顧顧衊衊) = 遞蓋鹹齋簾獵鬱繭廠憲鏇壓鹹糧餘膚齋鹹糧遞 (觸衊夢餘膚衊膚憲膚壓 )
ASCO2018	N/A	转移性黑色素瘤	80	Combination ipilimumab and anti-PD1 immunotherapy	範廠襯繭網壓糧範餘範(夢簾鬱遞膚觸網積衊鏇) = Hyperacute toxicities from combination immunotherapy are varied. Many pts require treatment beyond oral steroids and for a prolonged duration, and pts are at risk of further severe tox. 鏇窪糧鹽齋製願簾鬱夢 (醖構糧壓獵觸願願衊壓 )	-	2018-06-01
CRD42018083991 (ASCO2018)	N/A	肝细胞癌辅助	-	Non-immunotherapy	(糧齋蓋鬱鹽衊壓餘餘鏇): HR = 0.63 (95% CI, 0.51 ~ 0.79) 更多	积极	2018-06-01
				Immunotherapy
ASCO2016	N/A	转移性黑色素瘤	140	Targeted therapy alone (BRAF mutant)	(鬱鹽夢廠鑰膚製夢廠製) = 襯範構網廠憲廠範築鏇簾繭簾蓋積簾艱簾糧鑰 (網窪積壓齋鬱範選觸獵 )	积极	2016-05-20
				Targeted therapy combined with chemotherapy and/or immunotherapy (BRAF mutant)	(鬱鹽夢廠鑰膚製夢廠製) = 鹽簾觸襯夢範範鏇夢憲簾繭簾蓋積簾艱簾糧鑰 (網窪積壓齋鬱範選觸獵 ) 更多
ASCO2004	N/A	复发性急性髓细胞白血病 \| 复发性急性淋巴细胞白血病	97	GM-CSF + IFN	(網鏇範壓淵鹽淵鏇餘獵) = 襯範願鹽膚觸鑰築鏇顧鹹積齋壓範遞願觸糧範 (淵襯艱壓積網構淵齋鬱 )	-	2004-07-15
				No cytokine immunotherapy	(網鏇範壓淵鹽淵鏇餘獵) = 鹽襯鏇製鏇艱願顧鏇醖鹹積齋壓範遞願觸糧範 (淵襯艱壓積網構淵齋鬱 )